Ixekizumab: A Review of Its Use for the Management of Moderate to Severe Plaque Psoriasis
出版年份 2018 全文链接
标题
Ixekizumab: A Review of Its Use for the Management of Moderate to Severe Plaque Psoriasis
作者
关键词
-
出版物
ANNALS OF PHARMACOTHERAPY
Volume -, Issue -, Pages 106002801879998
出版商
SAGE Publications
发表日期
2018-09-06
DOI
10.1177/1060028018799982
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension
- (2018) A Kimball et al. ACTA DERMATO-VENEREOLOGICA
- Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab
- (2018) R.B. Warren et al. BRITISH JOURNAL OF DERMATOLOGY
- Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis
- (2018) April W. Armstrong et al. CURRENT MEDICAL RESEARCH AND OPINION
- Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States
- (2018) Jashin J. Wu et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis
- (2018) Jawad Bilal et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Maintenance of Skin Clearance With Ixekizumab Treatment of Psoriasis: Three-Year Results From the UNCOVER-3 Study
- (2018) Craig Leonardi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis
- (2018) Anne M. Loos et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies
- (2018) Jorge R. Georgakopoulos et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Inflammatory bowel disease events after exposure to the IL-17 inhibitors, secukinumab and ixekizumab: A post-marketing analysis from the RADAR (Research on Adverse Drug events And Reports) Program
- (2018) Kelsey A. Orrell et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis
- (2018) Claus Zachariae et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials
- (2017) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data
- (2017) Bruce Strober et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis
- (2017) K. Reich et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis
- (2017) A. Blauvelt et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3
- (2017) C.L. Leonardi et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials
- (2017) L. Guenther et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials
- (2017) C. Paul et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)
- (2016) Kristian Reich et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)
- (2016) Hidehisa Saeki et al. JOURNAL OF DERMATOLOGY
- Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials
- (2016) Alexandra B. Kimball et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A)
- (2016) K. Callis Duffin et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3
- (2016) P. van de Kerkhof et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies
- (2016) A.B. Gottlieb et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
- (2016) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-17 Antagonists in the Treatment of Psoriasis
- (2015) Shivani Felicia Chandrakumar et al. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
- Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis
- (2015) R.G. Langley et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Psoriasis
- (2015) Wolf-Henning Boehncke et al. LANCET
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
- (2015) Christopher E M Griffiths et al. LANCET
- Population exposure-response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis
- (2014) Lai-San Tham et al. JOURNAL OF CLINICAL PHARMACOLOGY
- A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis
- (2014) Kenneth B. Gordon et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Living with Psoriasis: Prevalence of Shame, Anger, Worry, and Problems in Daily Activities and Social Life
- (2013) F Sampogna et al. ACTA DERMATO-VENEREOLOGICA
- Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis
- (2013) B. Zhu et al. BRITISH JOURNAL OF DERMATOLOGY
- Consensus Guidelines for the Management of Plaque Psoriasis
- (2012) Sylvia Hsu ARCHIVES OF DERMATOLOGY
- Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
- (2012) Craig Leonardi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Guidelines of care for the management of psoriasis and psoriatic arthritis
- (2011) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study
- (2010) M. C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Guidelines of care for the management of psoriasis and psoriatic arthritis
- (2009) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
- (2008) W Wang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Guidelines of care for the management of psoriasis and psoriatic arthritis
- (2008) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started